Trials / Sponsors / Anwaar Saeed
Anwaar Saeed
Academic / Other · 5 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarci Pancreatic Adenocarcinoma | Phase 1 | 2025-09-22 |
| Recruiting | Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) Hepatocellular Carcinoma | Phase 2 | 2024-12-18 |
| Terminated | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer MSI-H Colorectal Cancer | Phase 2 | 2024-06-26 |
| Terminated | 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma | Phase 2 | 2022-01-26 |
| Recruiting | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other G Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2018-10-22 |